• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    3/10/21 2:57:02 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care
    Get the next $BEAT alert in real time by email
    SC 13G/A 1 arrowmark-beat022621a2.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*



    BioTelemetry, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

    090672106

    (CUSIP Number)

     

     

    February 28, 2021
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No. 090672106
     SCHEDULE 13G/A
    Page 2 of 6 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    ArrowMark Colorado Holdings, LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware, United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    0
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    0
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0.0%
    12
    TYPE OF REPORTING PERSON
     
    IA

     

     
     

     

    CUSIP No.  090672106
     SCHEDULE 13G/A
    Page 3 of  6 Pages

     

    Item 1.(a) Name of Issuer

    BioTelemetry, Inc.

    (b) Address of Issuer’s Principal Executive Offices

    1000 Cedar Hollow Road

    Malvern, Pennsylvania 19355

    Item 2.(a) Name of Person Filing

    ArrowMark Colorado Holdings, LLC

    (b) Address of Principal Business Office, or, if none, Residence

    100 Fillmore Street, Suite 325

    Denver, Colorado 80206

    (c) Citizenship

    Please refer to Item 4 on each cover sheet for each filing person

     (d) Title of Class of Securities

    Common Stock, par value $0.001 per share

     (e) CUSIP No.:

    090672106

     
     

     

    CUSIP No.  090672106
     SCHEDULE 13G/A
    Page 4 of 6 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

     
     

     

    CUSIP No. 090672106
     SCHEDULE 13G/A
    Page 5 of 6 Pages

     

     

    Item 4. Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a) Amount beneficially owned: 0

    (b) Percent of class: 0.0%

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote: 0

    (ii) Shared power to vote or to direct the vote: 0

    (iii) Sole power to dispose or to direct the disposition of: 0

    (iv) Shared power to dispose or to direct the disposition of: 0

    Item 5. Ownership of Five Percent or Less of a Class

     

    Not Applicable

     Item 6. Ownership of More Than Five Percent on Behalf of Another Person

     

    Not Applicable

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Not Applicable

    Item 8. Identification and Classification of Members of the Group

     

    Not Applicable

    Item 9. Notice of Dissolution of Group

     

    Not Applicable

    Item 10. Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

      

     
     
    CUSIP No. 090672106
     SCHEDULE 13G/A
    Page 6 of 6 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: March 10, 2021

     

     

      ArrowMark Colorado Holdings, LLC
           
      By:  Richard Grove
        Name:  Richard Grove
        Title:  Chief Compliance Officer

     

     

     

     

     

     

     

    Get the next $BEAT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BEAT

    DatePrice TargetRatingAnalyst
    12/20/2021$9.00Speculative Buy
    Benchmark
    More analyst ratings

    $BEAT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Benchmark initiated coverage on BioTelemetry with a new price target

      Benchmark initiated coverage of BioTelemetry with a rating of Speculative Buy and set a new price target of $9.00

      12/20/21 7:19:06 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care

    $BEAT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ferrari Richard bought $50,000 worth of shares (29,412 units at $1.70), increasing direct ownership by 20% to 179,136 units (SEC Form 4)

      4 - HeartBeam, Inc. (0001779372) (Issuer)

      2/21/25 8:00:22 PM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • CFO Cruickshank Tim bought $30,000 worth of shares (17,647 units at $1.70) (SEC Form 4)

      4 - HeartBeam, Inc. (0001779372) (Issuer)

      2/21/25 7:55:14 PM ET
      $BEAT
      Medical/Dental Instruments
      Health Care

    $BEAT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • HeartBeam to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24, 2025

      HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced that Robert Eno, Chief Executive Officer, and Timothy Cruickshank, Chief Financial Officer, will present at the iAccess Alpha Virtual Best Ideas Summer Conference on Tuesday, June 24, 2025. Eno and Cruickshank will also host virtual one-on-one meetings with institutional investors during the event. iAccess Alpha Virtual Summer Conference Dates: June 24-25, 2025 Location: Virtual Format: Presentation and Virtual 1x1 Meetings Attendees: Robert Eno, Chief Executive Officer, and Timothy Cruickshank, Chief Financial Officer Presentation T

      6/17/25 7:00:00 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • MDB Capital Holdings Provides First Quarter 2025 Update

      Addison, TX, May 21, 2025 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ:MDBH) ("MDB"), a public venture platform focused on launching category-leading disruptive technology companies, today provides an update on operations through and subsequent to the quarter ended March 31, 2025. First Quarter 2025 and Subsequent Operational Highlights Closed a public offering of common stock for HeartBeam, Inc (NASDAQ:BEAT) with gross proceeds of approximately $11.5 million. Completed LOIs for 3 new "Big Idea" companies to launch in 2025.Increased our MDBH shareholder base by 4.5% during Q1 2025.Onboarded 111 new MDB Direct accounts during the first quarter, a 26% i

      5/21/25 9:00:00 AM ET
      $BEAT
      $MDBH
      Medical/Dental Instruments
      Health Care
      Finance: Consumer Services
      Finance
    • HeartBeam Announces Two New U.S. Patents, Powering Forward Its Robust Patent Portfolio

      First patent significantly advances intellectual property for HeartBeam's credit card-sized ECG device, bolstering both the defensive and offensive moat around the company's core technology Second patent expands the use of risk-based diagnostic algorithms into HeartBeam's product portfolio around wearable devices HeartBeam now has 20 issued patents worldwide, cementing Company's leadership in cardiac monitoring innovation HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced the addition of two new U.S. patents, reinforcing its core intellectual property position and enabling futur

      5/6/25 7:00:00 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care

    $BEAT
    SEC Filings

    See more
    • SEC Form DEF 14A filed by Heartbeam Inc.

      DEF 14A - HeartBeam, Inc. (0001779372) (Filer)

      5/28/25 9:12:56 PM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • SEC Form PRE 14A filed by Heartbeam Inc.

      PRE 14A - HeartBeam, Inc. (0001779372) (Filer)

      5/16/25 9:10:31 PM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Heartbeam Inc.

      10-Q - HeartBeam, Inc. (0001779372) (Filer)

      5/13/25 4:04:02 PM ET
      $BEAT
      Medical/Dental Instruments
      Health Care

    $BEAT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Cruickshank Tim

      4 - HeartBeam, Inc. (0001779372) (Issuer)

      5/1/25 11:06:06 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Eno Robert Paul

      4 - HeartBeam, Inc. (0001779372) (Issuer)

      5/1/25 11:05:46 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Chief Technology Officer Persen Kenneth Harry

      4 - HeartBeam, Inc. (0001779372) (Issuer)

      5/1/25 11:03:46 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care

    $BEAT
    Financials

    Live finance-specific insights

    See more
    • HeartBeam to Host First Quarter 2025 Results Conference Call on Tuesday, May 13, 2025 at 4:30 p.m. Eastern Time

      HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, will hold a conference call on Tuesday, May 13, 2025 at 4:30 p.m. Eastern time to discuss its results for the first quarter ended March 31, 2025, and will be providing updates on regulatory initiatives, commercial-readiness activities and anticipated milestones. A press release detailing these results will be issued prior to the call. HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will host the conference call, followed by a question-and-answer period. The conference call will be accompanied by a presentation, which can be viewed during the web

      5/1/25 8:31:00 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • HeartBeam to Host Fourth Quarter Full Year 2024 Results Conference Call on Thursday, March 13, 2025 at 4:30 p.m. Eastern Time

      HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, will hold a conference call on Thursday, March 13, 2025 at 4:30 p.m. Eastern time to discuss its results for the fourth quarter and full year ended December 31, 2024, and will be providing updates on regulatory initiatives, commercial-readiness activities and anticipated milestones. A press release detailing these results will be issued prior to the call. HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will host the conference call, followed by a question-and-answer period. The conference call will be accompanied by a presentation, which can be

      2/27/25 8:31:00 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • HeartBeam Reports Third Quarter 2024 Results

      Continued Clinical and Regulatory Progress on the HeartBeam System Key Appointments to Management Team Completed as Part of Planned Evolution in Preparation for US Commercialization Strengthening Clinical Evidence Base, with Two Additional Studies to be Presented at the American Heart Association Conference in November 2024 Management to Host Webcast and Conference Call Today at 4:30 p.m. ET HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has reported its financial and operational results for the third quarter ended September 30, 2024. Third Quarter & Subsequent 2024 Operational Highlights

      11/7/24 4:05:00 PM ET
      $BEAT
      Medical/Dental Instruments
      Health Care

    $BEAT
    Leadership Updates

    Live Leadership Updates

    See more
    • HeartBeam Appoints CEO Robert Eno to Board of Directors to Support U.S. Commercialization and Growth

      Board expansion reflects Company's commitment to leadership and innovation in remote cardiac monitoring HeartBeam, Inc., (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced the appointment of Chief Executive Officer, Robert Eno, to its Board of Directors. As the Company continues to make significant advancements towards commercial readiness, the Board elected to expand from eight to nine members to accommodate this addition. Mr. Eno joined HeartBeam as President in January 2023 and was appointed CEO in October 2024. With over 30 years of experience in the medical technology industry, he has a proven

      5/5/25 7:00:00 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • HeartBeam Announces FDA Clearance for At-Home, High-Fidelity Heart Monitoring Technology

      First cable-free, ambulatory ECG that captures the heart's electrical signals from three distinct directions for high-fidelity data collection and advanced diagnostics Patients can have the credit card-sized device with them at all times, ready to record an ECG whenever they feel symptoms and reduce delays in care Company to initiate Early Access Program to gain important patient and physician feedback on the use of the system in preparation for commercial launch HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that the US Food and Drug Administration (FDA) has granted 510(k) cl

      12/16/24 8:31:00 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • HeartBeam Appoints Robert Eno as Chief Executive Officer in Preparation for US Commercialization

      Industry leader brings extensive experience in developing go-to-market strategies for breakthrough products and delivering growth Founder and current CEO Branislav Vajdic named President to focus on advancing the Company's groundbreaking vector-based technology for heart health, including AI applications HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful insights wherever the patient is, announced that Robert Eno has been appointed Chief Executive Officer (CEO), effective Monday, October 21, 2024. The seasoned MedTech executive joined HeartBeam as President in January 2023 and will lead as the Company continues to work

      10/17/24 8:31:00 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care

    $BEAT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Heartbeam Inc.

      SC 13D - HeartBeam, Inc. (0001779372) (Subject)

      10/25/23 4:01:55 PM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D filed by Heartbeam Inc.

      SC 13D - HeartBeam, Inc. (0001779372) (Subject)

      8/28/23 4:26:34 PM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D filed by Heartbeam Inc.

      SC 13D - HeartBeam, Inc. (0001779372) (Subject)

      6/2/23 2:36:13 PM ET
      $BEAT
      Medical/Dental Instruments
      Health Care